Moderna Inc. ($MRNA) Stock Forecast: Down 9.9% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its development of mRNA-based vaccines, including the widely used COVID-19 vaccine. The stock is listed on the NASDAQ.

Why is Moderna Inc. going down?

MRNA stock is down 9.9% on Aug 1, 2025 17:56

• Moderna (MRNA) stock experienced a bearish movement due to several factors:
• Moderna reported a Q2 loss of $2.13 per share, although it beat revenue estimates. The decrease in revenue by 41% from 2024 was mainly attributed to a decline in COVID-19 vaccine sales.
• Novavax's stock also dipped, possibly contributing to negative sentiment in the vaccine sector after Moderna's disappointing Q2 results.
• Despite some bullish options trading trends observed, the overall market sentiment was impacted by Moderna's financial performance and reduced revenue outlook for 2025.
• The combination of a loss in revenue, reduced revenue outlook, and a general downtrend in the vaccine sector likely led to the bearish movement in Moderna's stock.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/trading-ideas/movers/25/08/46799525/novavax-stock-dips-as-modernas-woes-weigh-on-vaccine-sector

Unpacking the Latest Options Trading Trends in Moderna - Moderna ( NASDAQ:MRNA )

Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/25/08/46797971/unpacking-the-latest-options-trading-trends-in-moderna

Why Is Moderna Stock Falling Friday? - Moderna ( NASDAQ:MRNA )

Moderna posted a Q2 loss of $2.13 per share, beating the $ ( 2.98 ) estimate and improving from $ ( 3.33 ) a year ago. Q2 revenue hit $142 million, topping expectations but down 41% from 2024 due to falling COVID-19 vaccine sales.

https://www.benzinga.com/markets/earnings/25/08/46791309/modernas-key-patent-win-overshadowed-by-gloomy-outlook

Moderna ( MRNA ) Reports Q2 Loss, Beats Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of +28.76% and +11.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2648536/moderna-mrna-reports-q2-loss-beats-revenue-estimates

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna also lost less than Wall Street analysts were expecting for the second quarter and posted revenue that topped estimates.

https://www.cnbc.com/2025/08/01/moderna-mrna-q2-2025-earnings.html

Trending Today

Emerson Electric Company ($EMR) Stock Forecast: Down 2.0% Today

Parker-Hannifin Corporation ($PH) Stock Forecast: Down 2.1% Today

Analog Devices Inc. ($ADI) Stock Forecast: Down 1.2% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Down 2.6% Today

Yum! Brands Inc. ($YUM) Stock Forecast: Down 1.3% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Down 1.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.3% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Down 1.4% Today

DuPont de Nemours Inc. ($DD) Stock Forecast: Up 1.2% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Moderna Inc. Price History

01.07.2025 - MRNA Stock was down 13.0%

• Moderna reported a Q2 loss per share, surpassing expectations, which likely disappointed investors.
• The decline in revenue, mainly attributed to decreased COVID-19 vaccine sales, likely influenced the stock's bearish movement.
• The revised revenue forecast and company downsizing announcement may have heightened concerns about Moderna's future growth prospects.
• Overall, the market responded negatively to Moderna's financial results and the challenges faced in the COVID-19 vaccine sector, resulting in the stock's downward movement.

24.05.2025 - MRNA Stock was up 5.4%

• Moderna's stock had a strong bullish movement today, closing at $25.90 with a +1.97% shift.
• The bullish movement could be attributed to positive developments related to the company's pipeline or vaccine distribution.
• Despite the bullish movement, there are indications that deep-pocketed investors have taken a bearish stance on Moderna, as revealed by options records. This contrasting sentiment from big money investors could be due to concerns about future growth prospects or market conditions.

31.06.2025 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline today for the following reasons:
• The announcement of a 10% reduction in workforce hints at challenges affecting COVID-19 vaccine sales and regulatory issues, which could impact the company's revenue.
• The decrease in Covid shot sales and implementation of cost-cutting strategies suggest a shift in the company's growth path, dampening investor confidence.
• Concerns about Moderna's Q2 earnings report are looming, with anticipated drops in Spikevax sales and crucial pipeline advancements potentially fueling the negative stock trajectory.

10.06.2025 - MRNA Stock was up 5.1%

• Moderna's stock (MRNA) saw a notable uptrend subsequent to receiving full approval from the FDA for its COVID-19 vaccine for children aged 6 months and above.
• The extended approval for this younger age demographic suggests a wider market scope for Moderna's vaccine, fostering enhanced investor confidence and propelling the stock price upwards.
• This favorable development underscores Moderna's ongoing success in diversifying its vaccine portfolio and combatting the global health crisis, contributing to the bullish trend in the stock today.

10.06.2025 - MRNA Stock was up 5.4%

• Moderna (MRNA) stock showed significant bullish movement.
• The positive market trend may be linked to potential developments in Moderna's vaccines and therapeutics pipeline.
• Investors are likely responding favorably to updates on Moderna's ongoing research and development activities, leading to an increase in stock price.
• The bullish movement could also be influenced by general market positivity and investor trust in the biotechnology industry.

02.06.2025 - MRNA Stock was up 5.6%

• Moderna's stock (MRNA) witnessed a noticeable upward trend in the market today.
• The favorable market response is linked to the recent announcement regarding Moderna's mRNA flu vaccine, mRNA-1010, displaying 26.6% higher efficacy in adults aged 50 and above compared to conventional flu shots.
• Investors responded positively to the encouraging vaccine trial results, signaling Moderna's potential to maintain its forefront position in mRNA-based vaccine research.
• This development highlights Moderna's ongoing advancements in the healthcare sector, bolstering investor confidence and contributing to the stock's uptick.

29.06.2025 - MRNA Stock was down 5.4%

• Despite high expectations for Moderna's Q2 performance, the stock experienced a strong bearish movement today.
• The sharp decline in Spikevax sales and RSV uptake could have contributed to the bearish market movement.
• The market whales' bullish stance on MRNA options may not have been enough to counterbalance the disappointing Q2 results, leading to the bearish trend.
• Investors were anticipating a potential earnings beat from Moderna, but the actual results may have fallen short of these expectations, causing the bearish movement in the stock price.

12.05.2025 - MRNA Stock was down 5.1%

• Moderna (MRNA) saw a decline, potentially due to profit-taking following a period of strong performance.
• Positive outcomes from Novavax's COVID-flu combination shot trial may have diverted investor attention from Moderna temporarily.
• A legal win against Alnylam Pharmaceuticals in a patent dispute could have been overshadowed by broader market sentiment, impacting Moderna's stock negatively.
• Mirum Pharmaceuticals' financial results and subsequent stock movements could have influenced overall investor outlook on biotech stocks, including Moderna.

01.07.2025 - MRNA Stock was down 9.9%

• Moderna (MRNA) stock experienced a bearish movement due to several factors:
• Moderna reported a Q2 loss of $2.13 per share, although it beat revenue estimates. The decrease in revenue by 41% from 2024 was mainly attributed to a decline in COVID-19 vaccine sales.
• Novavax's stock also dipped, possibly contributing to negative sentiment in the vaccine sector after Moderna's disappointing Q2 results.
• Despite some bullish options trading trends observed, the overall market sentiment was impacted by Moderna's financial performance and reduced revenue outlook for 2025.
• The combination of a loss in revenue, reduced revenue outlook, and a general downtrend in the vaccine sector likely led to the bearish movement in Moderna's stock.

08.06.2025 - MRNA Stock was up 5.3%

• MRNA stock rose significantly following the CDC's decision to broaden recommendations for RSV vaccine to high-risk adults aged 50-59.
• The expanded guidance is anticipated to enhance the market accessibility of Moderna's RSV vaccine, mResvia, increasing investor confidence and boosting the stock price.
• This favorable development showcases Moderna's ongoing success in utilizing its advanced technology to address crucial healthcare needs, further establishing its position as a prominent player in the biotech industry.

06.05.2025 - MRNA Stock was up 5.3%

• Moderna (MRNA) witnessed a notable bullish movement in the market recently.
• This upward trend could be linked to a recent court ruling stating that SM-102, a crucial ingredient in Moderna's Spikevax COVID-19 vaccine, does not violate Alnylam Pharmaceuticals' mRNA patents. This legal victory likely boosted investor confidence in Moderna's vaccine technology and market position.
• Furthermore, reports of significant financial institutions taking bearish positions on Moderna may have presented a short-term buying opportunity for traders, resulting in increased demand for the stock and contributing to its bullish movement.
• Taken together, the positive legal outcomes and strategic trading activities are believed to have driven Moderna's stock price higher on the given day.

15.06.2025 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline, even though it recently received full FDA approval for its COVID-19 vaccine in pediatric patients.
• The market response could be linked to general market trends or profit-taking following recent stock increases.
• Investors may be considering various factors like market conditions and potential competition in the vaccine sector.
• Despite the decrease, Moderna's future in biotechnology appears promising, particularly given its successful vaccine innovations.